Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
  • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/12—Antidiarrhoeals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/02—Antidotes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• This invention relates to treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC) and other conditions associated wit C. difficile infection. More specifically, the invention concerns neutralization of C. difficile toxin B, a cytotoxin associated with CDAD, PMC and other conditions caused byC. difficile.
• CDAD Clostridium difficile associated diarrhea
• PMC pseudomembranous colitis
• Keighiey, M.R.B. "Antibiotic-associated pseudomembranous colitis: pathogenesis and management", Drugs, 20:449-56 (1980).
• Triadfilopoulos G., et al., "Differential effects oClostridium difficile toxin a and b on rabbit ileum", Gastroenterology, 93:273-9 (1987).
• Clostridium difficile is the major causative agent of antibiotic-associated bacterial diarrhea and pseudomembranous colitis (PMC) among mainly elderly patients in hospitals and long term care facilities [1 ,2].
• the organism cannot compete successfully with the normal microbial flora in the adult colon, but when the normal intestinal microflora is altered, for example by antibiotic treatment.C. difficile is able to colonize the gut in high numbers.
• Antibiotic therapy accounts for 98% of all cases c €. difficile associated diarrhea (CDAD).
• CDAD c €. difficile associated diarrhea
• any predisposing condition which alters the normal intestinal flora including any condition which requires extensive immunosuppressive treatment, can also lead to the development of CDAD.
• AIDS patients are also high risk candidates for acquiring CDAD [3,4].
• C. difficile produces two exotoxins, toxin A (an enterotoxin) and toxin B (a cytotoxin) which appear to play important roles in causing CDAD. It has long been thought that toxin A is primarily responsible for the disease. It acts by binding to epithelial cells in the intestine, resulting in the destruction of these cells and causing the secretion of fluid into the intestine. The destruction of these protective epithelial cells by toxin A represents the crucial step leading to the development of diarrhea. Once damage has occurred to the epithelial cells, the potent cytotoxin B can then gain access to underlying sensitive tissues and initiate additional clinical symptoms [5- 10,13,19-20,53-56,57-59,61-64].
• toxin B was found to be more potent at damaging human colonic epithelium than toxin A, suggesting that toxin B may play a more important role in CDAD than previously believed.
• Toxin A has been found to display a lectin-like activity which allows it to bind to an oligosaccharide receptor on epithelial cells.
• oligosaccharide sequences have been identified as potential receptors for toxin A [60,66].
• the cellular receptor for toxin B has not been determined, but there are some indications that toxin B binds to erythrocytes implying that a carbohydrate receptor may be involved in toxin B binding [47, 48].
• Steroids have also been proposed as potential receptors for toxin B [47].
• the current therapy for patients who suffer from CDAD or PMC is to remove the offending drug and begin oral administration of the antibiotics Metronidazole or Vancomycin along with fluid replacement [3,14]. Vancomycin is only used in certain situations when patients cannot tolerate or are not responsive to Metronidazole treatment. Vancomycin is not used routinely because of its high cost and the possibility that its overuse may encourage the development of Vancomycin-resistant microorganisms.
• Metronidazole therapy is effective in about 80% of the patients who suffer from CDAD or PMC. In about 20% of patients, the diarrhea returns after discontinuing antibiotic treatment [15]. In such individuals, episodes continue to recur until the normal intestinal flora is reestablished and the number of C. difficile organisms is reduced. This is a slow process, since antibiotics such as Metronidazole, which disturb the balance of the normal intestinal flora, are administered each time the diarrhea occurs.
• one method for detecting ⁇ . difficile in a sample is to culture the sample.
• the disadvantages of this method include the length of time required to obtain a result and interference by non-pathogenic, i.e. non-toxin producing ⁇ , difficile strains.
• a compound which can neutralize C. difficile toxin B and/or both C. difficile toxin A and toxin B.
• a preferred compound would be administered noninvasiveiy, such as orally, in a suitable pharmaceutical formulation.
• the invention provides compositions and methods for the prevention and treatment of antibiotic associated diarrhea, pseudomembranous colitis and other conditions caused b Clostridium difficile toxin B.
• the invention provides a method to bind and removeC. difficile toxin B from a sample suspected of containing said toxin B comprising contacting the sample with at least one toxin B binding oligosaccharide sequence covalently attached to an inert support through a non-peptidyl compatible linker arm under conditions wherein the toxin B is absorbed to the support; and separating the support containing the absorbed toxin B from the sample.
• the invention provides a method to prevent or ameliorate one or more conditions mediated byC. difficile toxin B in a patient suffering from or susceptible to said condition, comprising administering to the patient an effective amount of a composition comprising at least one toxin B binding oligosaccharide sequence covalently attached to a pharmaceutically acceptable inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin B, and wherein the composition is capable of being eliminated from the gastrointestinal tract.
• the invention provides a pharmaceutical composition useful in treating or preventing CDAD and related conditions initiated by C.
• oligosaccharide sequence covalently attached to a pharmaceutically acceptable inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin B, and a pharmaceutically acceptable carrier, wherein said composition is capable of being eliminated from the gastrointestinal tract.
• the invention provides a method to bind and remove C. difficile toxins A and B from a sample suspected of containing said toxins A and B comprising contacting the sample with at least one toxin A binding oligosaccharide sequence and at least one toxin B binding oligosaccharide sequence covalently attached to an inert support through a non-peptidyl compatible linker arm under conditions wherein the toxins are absorbed to the support; and separating the support containing the absorbed toxins from the sample.
• the invention provides a method to prevent or ameliorate one or more conditions mediated byC. difficile toxins A and B in a patient suffering from or susceptible to said condition, comprising administering to the patient an effective amount of a composition comprising at least one toxin A binding oligosaccharide sequence and at least one toxin B binding oligosaccharide sequence covalently attached to a pharmaceutically acceptable inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequences bind toxins A and B, and wherein the composition is capable of being eliminated from the gastrointestinal tract.
• the invention provides a pharmaceutical composition useful in treating or preventing CDAD and related conditions initiated by C.
• oligosaccharide sequence covalently attached to a pharmaceutically acceptable inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence(s) binds both toxin A and toxin B, and a pharmaceutically acceptable carrier, wherein said composition is capable of being eliminated from the gastrointestinal tract.
• Figures 1A and B illustrate the time and concentration dependent neutralization ofC. difficile toxin B activity using SYNSORB 5-128.
• Figure 2 illustrates that SYNSORB 5174, which has both the Cd and the isomaltose oligosaccharide covalently bound by their respective linkers, neutralized both toxin A and B activity.
• antibiotic-associated bacterial diarrhea refers to the condition wherein antibiotic therapy disturbs the balance of the microbial flora of the gut, allowing pathogenic organisms such a&lostridium difficile to flourish. These organisms cause diarrhea.
• Antibiotic-associated bacterial diarrhea includes such conditions asClostridium difficile associated diarrhea
• CDAD CDAD
• PMC pseudomembranous colitis
• biocompatible refers to chemical inertness with respect to human tissues or body fluids.
• compatible linker arm or “linker arm” refer to a moiety which serves to space the oligosaccharide structure from the biocompatible support and which is bifunctional wherein one functional group is capable of binding to a reciprocal functional group of the support and the other functional group is capable of binding to a reciprocal functional group of the oligosaccharide structure.
• Compatible linker arms preferred in the present invention are non-peptidyl spacer arms.
• oligosaccharide may be linked via an 8-methoxycarbonyloctyl linker or via another appropriate non-peptidyl linker, such as a urea-like linker arm of the formula -NH-(CH) m -NHC(O)NH-, where m is an integer of from about 2 to about 10.
• oligosaccharide means saccharides comprising 1 to about 20 saccharide moieties. Saccharide derivatives may also be used as saccharide moieties included in the term oligosaccharide [67-69].
• PMC pseudomembranous colitis
• enteritis refers to the inflammation of the mucous membrane of both small and large intestine with the formation and passage of pseudomembranous material (composed of fibrin, mucous, necrotic epithelial cells and leukocytes) in the stools.
• support refers to an inert material to which the oligosaccharide sequences may be bound or immobilized via a compatible linker arm. Where use ⁇ sin vivo, the support will be biocompatible.
• SYNSORB refers to 8-methoxycarbonyloctyl oligosaccharide structures covalently coupled to Chromosorb F (Manville Corp., Denver, Colorado) [12], a derivatized silica particle material. Where indicated, the SYNSORB may use a urea-like linker arm rather than the 8- methoxycarbonyloctyl linker.
• toxin A refers to an enterotoxin ofOlostridium difficile which initiates CDAD and related conditions. This toxin has a lectin-like activity.
• toxin B refers to a cytotoxin oiClostridiu difficile which causes destruction of intestinal cells and induces the release of inflammatory mediators.
• all sugars are referenced using conventional three letter nomenclature. All sugars are assumed to be in the D-form unless otherwise noted, except for fucose, which is in the L-form. Further all sugars are in the pyranose form.
• the oligosaccharide isomaltotriose (xGlc(1-6) ⁇ Glc(1-6)Glc) was immobilized by attachment onto Chromosorb P using a linker arm, and tested in toxin B neutralization experiments.
• Concentration neutralization experiments were performed by incubating immobilized isomaltotriose (10, 20 or 40 mg) with 1 mL of toxin B for 2 hours at room temperature. The amount of toxin activity in each sample was measured using Chinese hamster ovary (CHO) cells.
• results are presented as the percent activity remaining relative to control toxin solutions that had not been incubated with SYNSORB.
• Time dependent neutralization experiments were performed by incubating toxin B with 20 mg samples of immobilized isomaltotriose SYNSORB for 1 , 2 and 4 h at room temperature.
• a control incubation (4 h) of toxin B with Chromosorb P was included to determine the extent of background binding to the support.
• results are presented as the percent activity remaining relative to control toxin solutions that had not been incubated with
• SYNSORBs which incorporate oligosaccharides terminating in glucose or N-acetylglucosamine were also examined for toxin B binding by measuring the cytotoxic activity of toxin B with or without SYNSORB in CHO cells. Results of these studies are shown in Table 1 , where * indicates SYNSORBs using the urea-like linker arm.
• Toxin B but not toxin A binds to isomaltose ( ⁇ Glc(1-6)Glc).
• isomaltose ⁇ Glc(1-6)Glc.
• isomaltose was immobilized onto the support using the recently developed "Instasorb" linker arm technology as disclosed in PCT/CA97/00851 [70].
• the resulting SYNSORB (SYNSORB 5174, which has both oligosaccharides covalently bound by their respective linkers) was then tested for toxin A and B binding.
• SYNSORB Cd and isomaltose SYNSORB SYNSORB 179A
• SYNSORB 5174 neutralized both toxin A and B activity.
• the results also indicate the toxin neutralizing capacity of SYNSORB 5174 was comparable to SYNSORB Cd and SYNSORB 179A.
• a support comprising more than one oligosaccharide ligand can be used to bind both toxin A and toxin B.
• the chemical synthesis of all or part of the oligosaccharide glycosides first involves formation of a glycosidic linkage on the anomeric carbon atom of the reducing sugar or monosaccharide.
• an appropriately protected form of a naturally occurring or of a chemically modified saccharide structure (the glycosyl donor) is selectively modified at the anomeric center of the reducing unit so as to introduce a leaving group comprising halides, trichloroacetimidate, acetyl, thioglycoside, etc.
• the donor is then reacted under catalytic conditions well known in the art with an aglycon or an appropriate form of a carbohydrate acceptor which possesses one free hydroxyl group at the position where the glycosidic linkage is to be established.
• aglycon moieties are known in the art and can be attached with the proper configuration to the anomeric center of the reducing unit.
• Appropriate use of compatible blocking groups, well known in the art of carbohydrate synthesis, will allow selective modification of the synthesized structures or the further attachment of additional sugar units or sugar blocks to the acceptor structures.
• the saccharide glycoside can be used to effect coupling of additional saccharide unit(s) or chemically modified at selected positions or, after conventional deprotection, used in an enzymatic synthesis.
• chemical coupling of a naturally occurring or chemically modified saccharide unit to the saccharide glycoside is accomplished by employing established chemistry well documented in the literature [21-37].
• the supports to which the oligosaccharide structures of the present invention are bound or immobilized include a wide variety of biocompatible materials known in the art.
• Water soluble biocompatible polymers such as hydrogels, carboxymethyl celluloses, synthetic polymers, and the like are particularly preferred.
• these supports are useful for delivery to the gut, especially prolonged delivery.
• Useful supports are non- absorbable, that is to say that they may be soluble or insoluble, so long as they are not absorbed by the body.
• Solid supports are particularly useful for certain applications. Such solid supports to which the oligosaccharide structures of the present invention are bound may be in the form of sheets or particles.
• a large variety of biocompatible solid support materials are known in the art. Examples thereof are silica, synthetic silicates such as porous glass, biogenic silicates such as diatomaceous earth, silicate-containing minerals such as kaolinite, and synthetic polymers such as polystyrene, polypropylene, and polysaccharides.
• the solid supports have a particle size of from about 10 to 500 microns fotin vivo use. In particular, particle sizes of 100 to 200 microns are preferred.
• the oligosaccharide structure(s) is covalently bound or noncovalently (passively) adsorbed onto the support so as to be immobilized.
• the covalent bonding may be via reaction between functional groups on the support and the compatible linker arm of the oligosaccharide structure. It has unexpectedly been found that attachment of the oligosaccharide structure to the biocompatible support through a compatible linking arm provides a product which, notwithstanding the support, effectively removes toxin.
• Linking moieties that are used in indirect bonding are preferably organic bifunctional molecules of appropriate length (at least one carbon atom) which serve simply to distance the oligosaccharide structure from the surface of the support.
• compositions of this invention are preferably represented by the formula: (OLIGOSACCHARIDE-Y-R) n -SUPPORT
• OLIGOSACCHARIDE represents an oligosaccharide group of at least 1 sugar unit which group binds to toxin B or toxins A and B
• Y is oxygen, sulfur or nitrogen
• R is an aglycon linking arm of at least 1 carbon atom
• SUPPORT is as defined above
• n is an integer greater than or equal to 1. Oligosaccharide sequences containing about 2 to 10 saccharide units may be used. Sequences with about 2 to 4 saccharide units are preferred.
• more than one oligosaccharide group may be linked to the support, e.g., one oligosaccharide group which binds toxin B and another which binds toxin A, to provide a composition which binds to more than one toxin moiety.
• Numerous aglycon linking arms are known in the art.
• a linking arm comprising a para-nitrophenyl group i.e., -OGH 4 pNO 2
• the nitro group is reduced to an amino group which can be protected as N- trifluoroacetamido.
• the trifluoroacetamido group Prior to coupling to a support, the trifluoroacetamido group is removed thereby unmasking the amino group.
• linking arm containing sulfur has been disclosed [39]. Specifically, the linking arm is derived from a 2-bromoethyl group which, in a substitution reaction with thionucleophiles, has been shown to lead to linking arms possessing a variety of terminal functional groups such as, - OCH 2 CH 2 SCH 2 CO 2 CH 3 and -OCH 2 CH 2 SC 6 H 4 -pNH 2 . These terminal functional groups permit reaction to complementary functional groups on the support, thereby forming a covalent linkage to the support. Such reactions are well known in the art.
• a 6-trifluoroacetamido-hexyl linking arm, (-O-(CH) 6 -NHCOCF 3 ) has been disclosed [40] in which the trifluoroacetamido protecting group can be removed, unmasking the primary amino group used for coupling.
• allyl linking arms can be derivatized in the presence of 2-aminoethanethiol [45] to provide for a linking arm -OCH,CH 2 CH 2 SCH 2 CH 2 NH 2 .
• Other suitable linking arms have also been disclosed [21-23, 25, 26]. The particular linking employed to covalently attach the oligosaccharide group to the support is not critical.
• the aglycon linking arm is a hydrophobic group and most preferably, the aglycon linking arm is a hydrophobic group selected from the group consisting of
• SYNSORB Chromosorb F
• SYNSORBs In studies using rats (a widely accepted model for preclinical studies, since they are predictive of human response), SYNSORBs have been found to pass unaffected through the rat gastrointestinal tract. They were found to be eliminated completely and rapidly (99% eliminated in 72 hours) following oral administration. Additionally, the high density of oligosaccharide moieties on SYNSORBs is particularly useful for binding toxins which have carbohydrate binding affinity. For example, toxin A is thought to possess multiple oligosaccharide binding sites [11].
• Non-peptidyl linking arms are preferred for use as the compatible linking arms of the present invention.
• the use of glycopeptides is not desirable because glycopeptides contain several, often different, oligosaccharides linked to the same protein. Glycopeptides are also difficult to obtain in large amounts and require expensive and tedious purification. Likewise, the use of BSA or HSA conjugates is not desirable due to questionable stability in the gastrointestinal tract when given orally.
• Covalent attachment of an oligosaccharide group containing a toxin B binding unit through a non-peptidyl spacer arm to an inert support permits efficient binding and removal of toxin B or toxins A and B from a sample to be analyzed for the presence of toxin B (or toxins A and B) or from the intestine of a patient suffering from or susceptible to CDAD, PMC or another condition associated withC. difficile infection.
• the oligosaccharide is synthesized with this compatible linker arm attached (in non-derivatized form), highly pure compositions may be achieved which can be coupled to various supports.
• compositions comprising one or more oligosaccharide structures which bind toxin B attached to a support.
• compositions When used for oral administration, which is preferred, these compositions may be formulated in a variety of ways. It will preferably be in liquid or semisolid form. Compositions including a liquid pharmaceutically inert carrier such as water may be considered for oral administration. Other pharmaceutically compatible liquids or semisolids, may also be used. The use of such liquids and semisolids is well known to those of skill in the art. (See, e.g., Remington's Pharmaceutical Sciences, 18th edition, 1990.)
• compositions which may be mixed with liquid or semisolid foods such as enteral nutritional formulas, applesauce, ice cream or pudding may also be preferred.
• Formulations such as SYNSORBs, which do not have a disagreeable taste or aftertaste are preferred.
• a nasogastric tube may also be used to deliver the compositions directly into the stomach.
• Solid compositions may also be used, and may optionally and conveniently be used in formulations containing a pharmaceutically inert carrier, including conventional solid carriers such as lactose, starch, dextrin or magnesium stearate, which are conveniently presented in tablet or capsule form.
• a pharmaceutically inert carrier including conventional solid carriers such as lactose, starch, dextrin or magnesium stearate, which are conveniently presented in tablet or capsule form.
• the (OLIGOSACCHARIDE-Y-R ⁇ -SUPPORT composition itself may also be used without the addition of inert pharmaceutical carriers, particularly for use in capsule form.
• Doses are selected to provide neutralization and elimination of toxin B found in the gut of effected or at risk subjects.
• Useful doses are from about 0.25 to 1.25 micromoles of oligosaccharide/kg body weight/day, preferably about 0.5 to 1.0 micromoles of oligosaccharide/kg body weight/day.
• SYNSORB compositions this means about 0.5 to 1.0 gram SYNSORB/kg body weight/day, which gives a concentration of SYNSORB in the gut of about 20 mg/ml.
• administration is expected to be 3 or 4 times daily, for a period of one week or until clinical symptoms are resolved.
• prolonged prophylactic administration e.g., in enteral nutritional formulas, is indicated.
• the dose level and schedule of administration may vary depending on the particular oligosaccharide structure used and such factors as the age and condition of the subject.
• formulations may also be considered for other means of administration such as per rectum.
• the usefulness of these formulations may depend on the particular composition used and the particular subject receiving the treatment.
• These formulations may contain a liquid carrier that may be oily, aqueous, emulsified or contain certain solvents suitable to the mode of administration.
• compositions may be formulated in unit dose form, or in multiple or subunit doses.
• orally administered liquid compositions should preferably contain about 1 micromole oligosaccharide/ml.
• C. difficile toxin B may be neutralized by certain oligosaccharide sequences which bind the toxin.
• synthetic oligosaccharides covalently attached to supports via non-peptidyl compatible linker arms have been found to neutralize toxin B or toxins A and B effectively.
• SYNSORBs which neutralize the activity of toxin B or toxins A and B.
• oligosaccharide sequences attached to Chromosorb P via 8-methoxylcarbonyloctyl (MCO) or urea-like spacer arms to neutralize toxin B or toxins A and B.
• MCO 8-methoxylcarbonyloctyl
• urea-like spacer arms to neutralize toxin B or toxins A and B.
• the oligosaccharide sequences attached to supports useful in the present invention are those which bind toxin B and, in some cases, both toxins A and B.
• oligosaccharide sequences attached to supports which bind toxin B means those compositions which reduce cytotoxicity in CHO cell assays by at least 50%.
• Treatment or prevention of CDAD, PMC or other conditions associated with C. difficile infection may be accomplished by oral administration of compositions containing oligosaccharide sequences covalently bound to a support via a compatible linker arm (e.g.,
• SYNSORBs For example, SYNSORBs have been found to pass through the stomach of rats intact. This means that they are intact when they contact toxin B in the intestinal tract. Subsequent elimination of intact SYNSORB with toxin B bound to it results in elimination of toxin B from the patient.
• Oligosaccharide sequences covalently attached via compatible linker arms to a support are useful to treat individuals who suffer from multiple episodes of diarrhea.
• patients Upon initial reoccurrence of diarrhea, patients would be treated with SYNSORB to remove toxin B or both toxin A and toxin B from the intestine.
• the removal of toxin A prevents the initial tissue damage to the intestinal lining, which leads to prevention or reduction of diarrhea.
• Removal of toxin B prevents the cytotoxicity of this toxin to the intestinal and colonic cells, which also leads to prevention or reduction of diarrhea.
• No further treatment with antibiotics need be given, allowing the re-establishment of the normal intestinal microflora within the gut. The advantage of such treatment is that it does not affect the recolonization of the intestinal tract by normal microflora.
• treatment with oligosaccharide sequences covalently attached via compatible linker arms to supports may be used to treat all individuals who suffer from or are prone to develop CDAD, PMC or other conditions associated withC. difficile infection.
• supports e.g., SYNSORBs
• the use of the oligosaccharide-support compositions of the present invention in combination with antibiotic therapy will be able to reduce the diarrhea more effectively, leading to more rapid recovery.
• Toxin B and/or toxin A may be measured directly on the surface of the oligosaccharide-containing support using any suitable detection system.
• any suitable detection system for example, radioactive, biotinylated or fluorescently labelled monoclonal or polyclonal antibodies specific for the toxin may be used to determine the amount of toxin bound to the support.
• radioactive, biotinylated or fluorescently labelled monoclonal or polyclonal antibodies specific for the toxin may be used to determine the amount of toxin bound to the support.
• a wide variety of protocols for detection of formation of specific binding complexes analogous to standard immunoassay techniques is well known in the art.
• Toxins A and B were isolated from a toxin producing strain oC difficile (ATCC 43255, VPI strain 10463) using slight modifications of the method of Sullivan et al. as described previously [2,21].
• the toxin B fraction was devoid of toxin A activity, as determined by the inability of the toxin containing solution to hemagglutinate rabbit erythrocytes.
• Fresh rabbit erythrocytes were washed once in Tris buffered saline (TBS, pH 7.4) and resuspended at a concentration of 4% (vol/vol) in TBS. Serial two-fold dilutions (50 L) of toxin A solutions were made in TBS in U-shaped microtitre wells. An equal volume (50 ⁇ L) of rabbit erythrocytes was then added to each well and the microtitre plate was mixed gently.
• Toxin A hemagglutination assays were incubated at 4C for 4 h. The hemagglutination titre was then assessed visually. All assays were done in duplicate. 3. Assay of Toxin B Activity Using Chinese Hamster Ovarv Cells
• CHO cells Chinese hamster ovary (CHO) cells were maintained in Hams F12 media supplemented with 10% fetal bovine serum in an atmosphere of 5% CO 2 at 37°C. Samples to be tested for toxin B activity were diluted 1 :10 in Hams media and filter sterilized through 0.22 micron syringe filters.
• Samples were serial 3-fold diluted in media and 10Q L of each dilution was added to wells with confluent monolayers of CHO cells and incubated for 24 h at 37° C / 5%CO 2 .
• the conditions required for toxin B binding were determined by incubating 20 mg samples of isomaltotriose SYNSORB (5-128) or Chromosorb with 1 mL of a purified toxin B solution in 1.5 mL microcentrifuge tubes for 1 , 2 and 4 h at room temperature on an end-over- end rotator. Control tubes containing toxin B solution but no SYNSORB or Chromosorb were incubated at the same time. Determination of the optimal amount of isomaltotriose SYNSORB required for maximum toxin B neutralization was performed by incubating immobilized isomaltotriose (10, 20 or 40 mg) with 1 mL of toxin B for 2 hours at room temperature.
• the oligosaccharides tested except ⁇ GIc effectively neutralized toxin B cytotoxicity.
• the oligosaccharides ⁇ Glc(1-2) ⁇ Gal, ⁇ Glc(1-4) ⁇ Glc (maltose), ⁇ Glc(1-4) ⁇ Glc (cellobiose), ⁇ Glc(1-6) ⁇ Glc(1-6) ⁇ Glc (isomaltotriose), ⁇ Glc(1-6) ⁇ Glc (isomaltose) and ⁇ GlcNAc(1-4) ⁇ GlcNAc (chitobiose) bound toxin B.
• Neutralization experiments were done by incubating either SYNSORB 5174, 179A (isomaltose) or Cd at a concentration of 20 mg/ mL with toxin A for 1 h or toxin B for 4 hours at room temperature. The amount of toxin activity in each sample was measured using CHO cells or rabbit erythrocytes. The results are presented as the percent activity remaining relative to control toxin solutions that had not been incubated with SYNSORB.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Inorganic Chemistry (AREA)
• Biochemistry (AREA)
• Ceramic Engineering (AREA)
• Toxicology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22189033

Family Applications (1)

Country Status (10)

Cited By (3)

Families Citing this family (17)

Citations (3)

Family Cites Families (8)

• 1998
  • 1998-05-28 US US09/085,032 patent/US6013635A/en not_active Expired - Fee Related
• 1999
  • 1999-05-27 JP JP2000550491A patent/JP2002516284A/ja active Pending
  • 1999-05-27 CN CN99805510A patent/CN1298306A/zh active Pending
  • 1999-05-27 EP EP06009088A patent/EP1704865A3/en not_active Withdrawn
  • 1999-05-27 CA CA002321927A patent/CA2321927A1/en not_active Abandoned
  • 1999-05-27 AU AU41253/99A patent/AU4125399A/en not_active Abandoned
  • 1999-05-27 AT AT99924602T patent/ATE387205T1/de not_active IP Right Cessation
  • 1999-05-27 EP EP99924602A patent/EP1089740B8/en not_active Expired - Lifetime
  • 1999-05-27 WO PCT/CA1999/000484 patent/WO1999061031A1/en not_active Ceased
  • 1999-05-27 DE DE1089740T patent/DE1089740T1/de active Pending
  • 1999-05-27 DE DE69938241T patent/DE69938241T2/de not_active Expired - Fee Related
  • 1999-10-18 US US09/419,790 patent/US6107282A/en not_active Expired - Fee Related
• 2000
  • 2000-06-13 US US09/593,040 patent/US6465435B1/en not_active Expired - Fee Related
  • 2000-11-27 NO NO20005992A patent/NO20005992L/no not_active Application Discontinuation
• 2006
  • 2006-05-16 JP JP2006136969A patent/JP2006213735A/ja active Pending

Patent Citations (4)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events